For Rectal and Intramuscular Use Only
in Pediatric Patients
A rapid, ultrashort-acting barbiturate anesthetic. Brevital® Sodium for injection is a freeze-dried, sterile, nonpyrogenic mixture of methohexital sodium with 6% anhydrous sodium carbonate added as a buffer. It contains not less than 90% and not more than 110% of the labeled amount of methohexital sodium. It occurs as a white, freeze-dried plug that is freely soluble in water.
This product is oxygen sensitive. The pH of the 1% solution is between 10 and 11; the pH of the 0.2% solution in 5% dextrose is between 9.5 and 10.5.
- Convenient and economical
- Reconstituted solutions are chemically stable at room temperature for 24 hours
- MultiDose vials are available in single packs for easy storage
- Latex-free
- Preservative-free and sulfur-free formulation
- Robust product supply
Brevital Sodium C-IV (methohexital for injection, USP) is manufactured and distributed by JHP Pharmaceuticals L.L.C.
JHP Pharmaceuticals, located in Rochester, Michigan, is an integrated specialty healthcare company that specializes in sterile injectable products. JHP manufactures and sells brand aseptic injectable pharmaceuticals in hospital and clinical settings and provides contract manufacturing services for global pharmaceutical companies. JHP's own product portfolio includes leading diagnostic, women's health and anesthesia products. All products have a long track record of "gold standard" service and are at or near the front line of treatment in their therapeutic indications. Contract manufactured products include some of the leading global biologic products which involve liquid, lyophilized and suspension presentations.
WARNING
Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See WARNINGS)